Search for: "In re Onglyza (Saxagliptin) and Kombiglyze (Saxagliptin and Metformin) Products Liability Litigation"
Results 1 - 3
of 3
Sorted by Relevance
|
Sort by Date
12 Feb 2018, 12:05 pm
This Diabetes Drugs Litigation Involves Heart Failure, Myocardial Infarction, And Other Cardiovascular Problems (Posted by Tom Lamb at DrugInjuryWatch.com) In February 2018 the United States Judicial Panel on Multidistrict Litigation (JPML) established MDL No. 2809, IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION. [read post]
21 Feb 2018, 1:40 pm
IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability Litigation MDL-2809 Number of lawsuits pending: 84 Diabetes drugs in this MDL case: Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin) Primary side effect for these cases: Heart Failure Get more information about these drug injury cases… [read post]
29 Mar 2018, 7:50 am
Overview of January 2018 Hearing Session Following the January 25, 2018 hearing session in Miami, Florida, the JPML issued transfer orders centralizing cases and creating new Multidistrict Litigation (“MDL”) in seven out of the thirteen new petitions: MDL No. 2809 – In Re: Onglyza (Sexagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability Litigation (Transferred to the Honorable… [read post]
